@prefix this: <http://www.tkuhn.ch/bel2nanopub/RA8-64glRPAQ_N-2NEUdj_7i98HvJKNSczeqj8P67MTjI> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RA8-64glRPAQ_N-2NEUdj_7i98HvJKNSczeqj8P67MTjI#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix schem: <http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-chemical-names/> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix proteinModification: <http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00000> .
@prefix psimod: <http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 belv:variantOf hgnc:3321;
    a proteinModification:, psimod:00696 .
  
  sub:_2 occursIn: species:9606;
    rdf:object sub:_1;
    rdf:predicate belv:increases;
    rdf:subject schem:trans10%2Ccis12-Octadecadienoate;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(SCHEM:\"trans10,cis12-Octadecadienoate\") -> p(HGNC:ELK1,pmod(P))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "1.4" .
  
  sub:_3 prov:value "Stromal vascular cultures containing newly differentiated human adipocytes were pretreated with a vehicle (dimethyl sulfoxide) for 1 hour, then with 1 microM BRL49653 (PPARgamma agonist) for 24hours and subsequently treated with 30microM trans-10, cis-12 conjugated linoleic acid for an additional 24hours. CLA treatment conferred the ability of ERK1/2 to phosphorylate its nuclear substrate ELK1 in vitro. Pretreatment with BRL49653 blocked the CLA mediated ability of ERK1/2 to phosphorylate ELK-1";
    prov:wasQuotedFrom pubmed:15067015 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:15067015;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:22.285+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}